Gemtuzumab ozogamicin
Mylotarg · Antibody-drug conjugate (CD33/calicheamicin)
Tumor lysis and veno-occlusive disease.
Antibody-drug conjugate (CD22/calicheamicin)
Besponsa · InO
Antibody-drug conjugate (CD22/calicheamicin) · approved 2017 · 4 citations · FAERS AKI reporting ROR 1.98 (95% CI 1.54–2.55, 62 AKI reports)
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
A CD22/calicheamicin conjugate for ALL — tumor lysis and veno-occlusive disease drive its renal risk.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Direct nephrotoxicity is not a prominent signal. AKI is chiefly secondary to tumor lysis and to hepatic sinusoidal obstruction syndrome/veno-occlusive disease (VOD) — a notable, sometimes fatal complication, particularly around subsequent allogeneic stem-cell transplant. Renal-specific incidence is not quantified.Source: Kantarjian et al., N Engl J Med 2016 (INO-VATE)
Early — tumor lysis during initial therapy (VOD, non-renal, is peri-transplant).
Distilled from: “Early — tumor lysis during initial therapy; VOD typically peri-transplant.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).
Intratubular precipitation of drug or metabolite — high-dose methotrexate and tumor lysis crystals.
Tap a signature to trace where it strikes the nephron.
Functional / pre-renal — reduced perfusion upstream of the nephron; no single structural segment is injured.
Prerenal / Hemodynamic AKI: functional / pre-renal, no single structural segment injured.
Prerenal / Hemodynamic AKI
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Antibody-drug conjugate targeting CD22 and delivering the DNA-damaging calicheamicin payload via a hydrolyzable linker. Approved for relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Class-level context for the major non-renal toxicities of the Antibody-drug conjugate (CD22/calicheamicin) class.
Hematologic
Cytopenias, thrombosis, TMA
Ophthalmic
Keratopathy, uveitis, retinopathy
Pulmonary
Pneumonitis, ILD, effusions, hypertension
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
4 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Quoted verbatim from this agent's current FDA label (Feb 2026) — not paraphrased or interpreted. Full label on DailyMed .
Boxed warning
WARNING: HEPATOTOXICITY, INCLUDING HEPATIC VENO-OCCLUSIVE DISEASE (VOD) (ALSO KNOWN AS SINUSOIDAL OBSTRUCTION SYNDROME) and INCREASED RISK OF POST-HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) NON-RELAPSE MORTALITY WARNING: HEPATOTOXICITY, INCLUDING HEPATIC VENO-OCCLUSIVE DISEASE (VOD) (ALSO KNOWN AS SINUSOIDAL OBSTRUCTION SYNDROME) and INCREASED RISK OF POST- HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) NON-RELAPSE MORTALITY See full prescribing information for complete boxed warning. • Hepatotoxicity, including fatal and life-threatening VOD occurred in patients who received BESPONSA. ( 5.1 ) • A higher post-HSCT non-relapse mortality rate occurred in patients receiving BESPONSA ( 5.2 ) HEPATOTOXICITY, INCLUDING VOD • Hepatotoxicity, including fatal and life-threatening VOD occurred in patients with relapsed or refractory acute lymphoblastic leukemia (ALL) who received BESPONSA. The risk of VOD was greater in patients who underwent HSCT after BESPONSA treatment; use of HSCT conditioning regimens containing 2 alkylating agents and last total bilirubin level ≥ upper limit of normal (ULN) before HSCT were significantly associated with an increased risk of VOD. • Other risk factors for VOD in patients treated with BESPONSA included ongoing or prior liver disease, prior HSCT, increased age, later salvage lines, and a greater number of BESPONSA treatment cycles. • Elevation of liver…
Kidney rows of the label's dosage tables
From the Besponsa label (Feb 2026) · DailyMed
No row of this label's 7 dosage tables names a kidney term together with a withhold, reduce, resume or discontinue instruction. That covers those four instructions in the tables only: a table can still set a starting dose by creatinine clearance, and the prose can give other kidney instructions. The full label on DailyMed has both.
Everything below is FAERS — adverse events someone chose to report, about 2,992 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Reported with a death outcome
1,018 of 2,992 reports
Reported with hospitalization
1,193 of 2,992 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 158 of the 2,992 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Inotuzumab ozogamicin sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Mylotarg · Antibody-drug conjugate (CD33/calicheamicin)
Tumor lysis and veno-occlusive disease.
Adcetris · Antibody-drug conjugate (CD30/MMAE)
Tumor lysis in lymphoma.
Polivy · Antibody-drug conjugate (CD79b/MMAE)
Tumor lysis; emerging renal data.
Epkinly · Bispecific (CD20×CD3)
CRS and tumor lysis — emerging.
Columvi · Bispecific (CD20×CD3)
CRS and tumor lysis — emerging.
Lunsumio · Bispecific (CD20×CD3)
CRS and tumor lysis in lymphoma.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.